Loading clinical trials...
Loading clinical trials...
An Open-label Trial to Assess Pharmacokinetics and Safety of Tiotropium + Olodaterol Fixed-dose Combination (5 µg/ 5 µg) Delivered by the RESPIMAT Inhaler After Single and Multiple Dose Treatment in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
Conditions
Interventions
Tiotropium
Olodaterol
Locations
1
China
West China Hospital
Chengdu, China
Start Date
February 24, 2017
Primary Completion Date
June 15, 2017
Completion Date
June 15, 2017
Last Updated
March 29, 2019
NCT06831994
NCT02755974
NCT05050591
NCT05913765
NCT05592847
NCT00683722
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions